Rocket Pharmaceuticals, Inc. (RCKT)

Over the past six months, Rocket Pharmaceuticals' stock price has experienced significant fluctuations. In October 2025, the FDA accepted Rocket Pharmaceuticals' BLA resubmission for KRESLADI™ (RP-L201), but the company also pulled its FDA application for RP-L102 gene therapy. In August 2025, the FDA lifted the clinical hold on the pivotal Phase 2 trial of RP-A501 for Danon disease. Rocket Pharmaceuticals reported its Third Quarter 2025 financial results in November 2025. Recent analyst actions in December 2025 and January 2026 show conflicting sentiments, with some lowering price targets and others cutting the stock due to risks to the Danon disease program.

Information regarding specific demand seasonality for Rocket Pharmaceuticals' products and services is not explicitly available. As a clinical-stage biopharmaceutical company, traditional demand seasonality does not directly apply to its current pipeline. The demand for its therapies is driven by the prevalence of the rare diseases it targets and the success of its clinical development and regulatory approval processes.

Rocket Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare pediatric diseases, utilizing both lentiviral and adeno-associated viral vector-based gene therapies. Its pipeline includes RP-L102 (KRESLADI™) for Fanconi Anemia, RP-L201 (KRESLADI™) for Leukocyte Adhesion Deficiency-I, RP-L301 for Pyruvate Kinase Deficiency, RP-A501 for Danon Disease, RP-A601 for Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), BAG3 Dilated Cardiomyopathy (BAG3-DCM), and RP-L401 for Infantile Malignant Osteopetrosis.

Rocket Pharmaceuticals is headquartered in Cranbury, New Jersey, and focuses on developing gene therapies for rare diseases in the United States. While its operations are primarily based in the US, its investor base includes the United States, Monaco, the United Kingdom, and other countries.

Rocket Pharmaceuticals' brand reputation has been influenced by clinical trial progress and regulatory interactions with the FDA. Positive news, such as the FDA's acceptance of the BLA resubmission for KRESLADI™ and the lifting of a clinical hold on the Danon disease study, led to positive sentiment. Conversely, the company's decision to pull the FDA application for RP-L102 gene therapy and analyst downgrades negatively impacted its reputation. The overall stock price decline suggests the company has faced challenges affecting its market perception.

Rocket Pharmaceuticals, Inc. has significant institutional ownership, with 91.19% of its shares held by institutions. Major institutional owners include Rtw Investments, Lp, Maverick Capital Ltd, and BlackRock, Inc. Insider ownership stands at 3.06%.